BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61:730-740. [PMID: 25987643 DOI: 10.1093/cid/civ396] [Cited by in Crossref: 184] [Cited by in F6Publishing: 167] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Gigi E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World J Hepatol 2018;10:595-602. [PMID: 30310537 DOI: 10.4254/wjh.v10.i9.595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology 2019;69:2349-63. [PMID: 30693573 DOI: 10.1002/hep.30527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T, Stättermayer AF, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS 2016;30:1039-47. [PMID: 26760453 DOI: 10.1097/QAD.0000000000001020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
4 Liu J, Guo M, Ke L, You R. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Front Public Health 2022;10:836986. [DOI: 10.3389/fpubh.2022.836986] [Reference Citation Analysis]
5 Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl 2017;23:1596-600. [PMID: 29024442 DOI: 10.1002/lt.24959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Kaohsiung J Med Sci. 2021;37:334-345. [PMID: 33151016 DOI: 10.1002/kjm2.12315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grgurevic I, Bozin T, Madir A. Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards? Clin Exp Hepatol. 2017;3:181-186. [PMID: 29255805 DOI: 10.5114/ceh.2017.71491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
8 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Béguelin C, Suter A, Bernasconi E, Fehr J, Kovari H, Bucher HC, Stoeckle M, Cavassini M, Rougemont M, Schmid P, Wandeler G, Rauch A; Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int 2018;38:424-31. [PMID: 28741901 DOI: 10.1111/liv.13528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
12 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
13 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Socías ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K, Debeck K, Milloy MJ. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int 2019;39:1400-7. [PMID: 30653809 DOI: 10.1111/liv.14043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
15 Hutchinson SJ, Valerio H, McDonald SA, Yeung A, Pollock K, Smith S, Barclay S, Dillon JF, Fox R, Bramley P, Fraser A, Kennedy N, Gunson RN, Templeton K, Innes H, McLeod A, Weir A, Hayes PC, Goldberg D. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut 2020;69:2223-31. [PMID: 32217640 DOI: 10.1136/gutjnl-2019-320007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
16 Schneider MD, Sarrazin C. Management of HCV-Associated Liver Cirrhosis. Visc Med 2016;32:96-104. [PMID: 27413726 DOI: 10.1159/000445330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Peiffer KH, Zeuzem S. [Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35006288 DOI: 10.1007/s00103-021-03481-z] [Reference Citation Analysis]
18 Butt AA, Yan P, Simon TG, Abou-Samra AB. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin Infect Dis. 2017;65:1006-1011. [PMID: 28903508 DOI: 10.1093/cid/cix364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
19 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Winston A, Wurcel AG, Gordon C, Goyal N. Viral hepatitis in patients on hemodialysis. Semin Dial 2020;33:254-62. [PMID: 32394502 DOI: 10.1111/sdi.12882] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 You MW, Kim KW, Shim JJ, Pyo J. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. J Gastroenterol Hepatol 2021;36:601-8. [PMID: 32875681 DOI: 10.1111/jgh.15243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
22 Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. Aliment Pharmacol Ther. 2016;44:145-156. [PMID: 27199103 DOI: 10.1111/apt.13673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
23 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Znoyko OO, Klimova EA, Maevskaya MV, Shuldyakov АA, Linkova YN, Morozova MA. [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice]. Ter Arkh 2016;88:156-62. [PMID: 28635836 DOI: 10.17116/terarkh20168811156-162] [Reference Citation Analysis]
25 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
26 Samuel ST, Martinez AD, Chen Y, Markatou M, Talal AH. Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. World J Hepatol 2018; 10(2): 319-328 [PMID: 29527267 DOI: 10.4254/wjh.v10.i2.319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
27 Wang HL, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:45-52. [PMID: 27597318 DOI: 10.1111/jgh.13587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
28 Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, Vera-Méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33:1167-74. [PMID: 30845068 DOI: 10.1097/QAD.0000000000002186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
29 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
30 Messori A, Badiani B, Trippoli S. Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. Clin Drug Investig 2015;35:843-50. [DOI: 10.1007/s40261-015-0338-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
31 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Yen YH, Kee KM, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One 2019;14:e0208858. [PMID: 30625158 DOI: 10.1371/journal.pone.0208858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Ridziauskas M, Zablockienė B, Jančorienė L, Samuilis A, Zablockis R, Jackevičiūtė A. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina (Kaunas) 2021;57:210. [PMID: 33652777 DOI: 10.3390/medicina57030210] [Reference Citation Analysis]
34 Doshi RK, Ruben M, Drezner K, Lachmann A, Kuo I, Chanes-Mora P, Varga L, Saafir-Callaway B, Visconti A, Kharfen M. Knowledge, Attitudes, and Behaviors Related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DC. J Community Health. 2020;45:785-794. [PMID: 32125591 DOI: 10.1007/s10900-020-00794-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017;12:e0185728. [PMID: 28977040 DOI: 10.1371/journal.pone.0185728] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
36 Fox R. Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers. Dig Dis Sci 2016;61:3381-3. [PMID: 27619392 DOI: 10.1007/s10620-016-4301-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Tronina O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M, Lisik W, Kosieradzki M, Durlik M. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplant Proc 2017;49:1409-18. [PMID: 28736015 DOI: 10.1016/j.transproceed.2017.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
38 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
40 Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, Postel N, Friedrich-Rust M, Hofmann WP; German Hepatitis C-Registry. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. J Viral Hepat 2020;27:690-8. [PMID: 32096310 DOI: 10.1111/jvh.13280] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
41 Maier MM, Zhou XH, Chapko M, Leipertz SL, Wang X, Beste LA. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. Dig Dis Sci 2018;63:1454-62. [PMID: 29453610 DOI: 10.1007/s10620-018-4956-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Serfaty L. Follow-up of patients with chronic hepatitis C and a sustained viral response. Liver Int. 2016;36 Suppl 1:67-71. [PMID: 26725900 DOI: 10.1111/liv.13016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
43 Mena A, Meijide H, Rodríguez-osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med 2017;18:685-9. [DOI: 10.1111/hiv.12502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
44 Crismale JF, Ahmad J. Expanding treatment for hepatitis C in Canada. CMAJ 2018;190:E667-8. [PMID: 29866891 DOI: 10.1503/cmaj.170931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
46 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
47 Uriarte-Pinto M, Navarro-Aznarez H, De La Llama-Celis N, Arazo-Garcés P, Martínez-Sapiña AM, Abad-Sazatornil MR. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. Int J Clin Pharm 2018;40:608-16. [PMID: 29556931 DOI: 10.1007/s11096-018-0621-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
49 Huynh T, Zhang J, Hu KQ. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. J Clin Transl Hepatol 2018;6:258-63. [PMID: 30271737 DOI: 10.14218/JCTH.2018.00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, Milloy MJ. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. HIV Med 2017;18:647-54. [PMID: 28294492 DOI: 10.1111/hiv.12501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
51 Calner P, Sperring H, Ruiz-Mercado G, Miller NS, Andry C, Battisti L, Scrudder K, Shea F, Chan A, Schechter-Perkins EM. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One 2019;14:e0218388. [PMID: 31291275 DOI: 10.1371/journal.pone.0218388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
52 Montazerhodjat V, Weinstock DM, Lo AW. Buying cures versus renting health: Financing health care with consumer loans. Sci Transl Med 2016;8:327ps6. [PMID: 26912902 DOI: 10.1126/scitranslmed.aad6913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
53 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
54 Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24. [PMID: 27186235 DOI: 10.1186/s13027-016-0071-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
55 Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, Darvishian M, Gilbert M, Wong J, Binka M, Alvarez M, Tyndall M, Krajden M, Janjua NZ. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Liver Int 2019;39:2261-72. [PMID: 31444846 DOI: 10.1111/liv.14227] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
56 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
57 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
58 Heath K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. Clinicoecon Outcomes Res 2018;10:539-50. [PMID: 30288069 DOI: 10.2147/CEOR.S171248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
60 Moore MS, Bocour A, Jordan L, McGibbon E, Varma JK, Winters A, Laraque F. Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City. J Public Health Manag Pract 2018;24:526-32. [PMID: 29227418 DOI: 10.1097/PHH.0000000000000688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology 2018;67:847-57. [PMID: 29108121 DOI: 10.1002/hep.29642] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
62 Schmidt FP, Zimmermann T, Wenz T, Schnorbus B, Ostad MA, Feist C, Grambihler A, Schattenberg JM, Sprinzl MF, Münzel T, Galle PR. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. International Journal of Cardiology 2018;271:296-300. [DOI: 10.1016/j.ijcard.2018.04.058] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
63 Sharafi H, Alavian SH, Behnava B, Saeid Rezaee-Zavareh M, Nikbin M, Alavian SM. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian J Intern Med 2020;11:41-6. [PMID: 32042385 DOI: 10.22088/cjim.11.1.41] [Reference Citation Analysis]
64 Corma-gómez A, Macías J, Téllez F, Freyre-carrillo C, Morano L, Rivero-juárez A, Ríos MJ, Alados JC, Vera-méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases 2019. [DOI: 10.1093/cid/ciz1140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
65 Mínguez C, García-Deltoro M, Flores J, Galindo MJ, Montero M, Reus S, Carmena J, Masiá M, Amador C, Ortega E; on the behalf of the COINFECOVA-2 study group. Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. AIDS 2018;32:337-46. [PMID: 29309345 DOI: 10.1097/QAD.0000000000001699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Messori A. Newest Treatments for Hepatitis C: How Can We Manage Sustainability? Clin Infect Dis 2015;61:1891-2. [PMID: 26261204 DOI: 10.1093/cid/civ667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
67 Peleg N, Issachar A, Sneh Arbib O, Cohen‐naftaly M, Harif Y, Oxtrud E, Braun M, Leshno M, Barsheshet A, Shlomai A. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat 2019;26:1257-65. [DOI: 10.1111/jvh.13167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
68 Rey D, Muret P, Piroth L. Optimum combination therapy regimens for HIV/HCV infection. Expert Rev Anti Infect Ther 2016;14:299-309. [PMID: 26822803 DOI: 10.1586/14787210.2016.1147952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Sikavi C, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. Dig Dis Sci 2018;63:2829-39. [PMID: 30094623 DOI: 10.1007/s10620-018-5215-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
70 Pascual-Argente N, Puig-Junoy J, Llagostera-Punzano A. Non-healthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:19-30. [PMID: 28844170 DOI: 10.1080/17474124.2017.1373016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
71 McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, Dillon JF, Fraser A, Innes HA, Kennedy N, Morris J, Went A, Hayes PC, Hutchinson SJ. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat 2020;27:270-80. [PMID: 31696575 DOI: 10.1111/jvh.13232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
72 Høj SB, Minoyan N, Artenie AA, Grebely J, Bruneau J. The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? CanLivJ 2018;1:4-13. [DOI: 10.3138/canlivj.1.2.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Greenaway C, Azoulay L, Allard R, Cox J, Tran VA, Abou Chakra CN, Steele R, Klein M. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis 2017;17:140. [PMID: 28193199 DOI: 10.1186/s12879-017-2242-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
74 Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Hepatobiliary Pancreat Dis Int 2019;18:143-8. [PMID: 30558838 DOI: 10.1016/j.hbpd.2018.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
76 Wittkop L. Editorial Commentary: End-Stage Liver Disease in HIV Infection: An Avoidable Burden? Clin Infect Dis 2016;63:1168-70. [PMID: 27506684 DOI: 10.1093/cid/ciw537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
78 Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018;17:377-84. [PMID: 30923667 DOI: 10.1007/s11901-018-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
79 Alvaro-Meca A, Ryan P, Micheloud D, De Miguel A, Berenguer J, Resino S. Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. Sci Rep 2018;8:12137. [PMID: 30108235 DOI: 10.1038/s41598-018-29739-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
81 Wei X, Zhao J, Yang L. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Glob Health 2020;5:e003194. [PMID: 33246983 DOI: 10.1136/bmjgh-2020-003194] [Reference Citation Analysis]
82 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
83 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
84 Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis 2020;222:1334-44. [PMID: 32406487 DOI: 10.1093/infdis/jiaa254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
86 Berenguer M, de la Rosa Rodríguez G, Domínguez-gil B. Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. Journal of Hepatology 2018;69:966-8. [DOI: 10.1016/j.jhep.2018.06.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
87 Alvaro-Meca A, Berenguer J, Díaz A, Micheloud D, Aldámiz-Echevarría T, Fanciulli C, Resino S. Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS One 2017;12:e0179493. [PMID: 28617855 DOI: 10.1371/journal.pone.0179493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
88 Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018;66:1742-50. [PMID: 29272349 DOI: 10.1093/cid/cix1106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
89 Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 257] [Cited by in F6Publishing: 195] [Article Influence: 128.5] [Reference Citation Analysis]
90 Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferrière V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. AIDS 2019;33:1013-22. [PMID: 30946155 DOI: 10.1097/QAD.0000000000002156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
91 Brouard C, Boussac-Zarebska M, Silvain C, Durand J, de Lédinghen V, Pillonel J, Delarocque-Astagneau E. Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. BMC Infect Dis 2017;17:784. [PMID: 29262788 DOI: 10.1186/s12879-017-2889-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
92 Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy 2018;62:94-103. [DOI: 10.1016/j.drugpo.2018.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
93 Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat 2020;27:671-9. [PMID: 32050037 DOI: 10.1111/jvh.13276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
94 Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L; EuroSIDA study group. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Med 2021. [PMID: 34882940 DOI: 10.1111/hiv.13212] [Reference Citation Analysis]
95 Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017; 23(26): 4669-4674 [PMID: 28765688 DOI: 10.3748/wjg.v23.i26.4669] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
96 Lapointe-Shaw L, Chung H, Sander B, Kwong JC, Holder L, Cerocchi O, Austin PC, Feld JJ. Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. Liver Int 2021;41:33-47. [PMID: 32956567 DOI: 10.1111/liv.14670] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Chen J, Li Y, Li G, Lei P. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. Ren Fail 2020;42:377-80. [PMID: 32301365 DOI: 10.1080/0886022X.2020.1753073] [Reference Citation Analysis]
98 Sandmann L, Deppe J, Beier C, Ohlendorf V, Schneider J, Wedemeyer H, Wedegärtner F, Cornberg M, Maasoumy B. Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. Open Forum Infect Dis 2021;8:ofab325. [PMID: 34377724 DOI: 10.1093/ofid/ofab325] [Reference Citation Analysis]
99 Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11:521-526. [PMID: 27716732 DOI: 10.1097/coh.0000000000000292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
100 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology 2019;69:487-97. [PMID: 28749564 DOI: 10.1002/hep.29408] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 37.0] [Reference Citation Analysis]
101 Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis 2016;63 Suppl 1:S3-S11. [PMID: 27363438 DOI: 10.1093/cid/ciw219] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
102 Cooke GS. Scaling-up HCV treatment to achieve WHO targets by 2030. Trop Med Int Health 2017;22:372-4. [DOI: 10.1111/tmi.12837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
103 Liu CJ, Tseng KC, Lo CC, Tseng IH, Cheng PN. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. J Formos Med Assoc 2020;119:933-40. [PMID: 31594667 DOI: 10.1016/j.jfma.2019.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
104 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
105 Alvaro-Meca A, Ryan P, Martínez-Larrull E, Micheloud D, Berenguer J, Resino S. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain. Eur J Intern Med 2018;48:69-74. [PMID: 29102088 DOI: 10.1016/j.ejim.2017.10.012] [Reference Citation Analysis]
106 Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci 2019;14:26. [PMID: 30866982 DOI: 10.1186/s13012-019-0861-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
107 Zoulim F, Moreno C, Lee SS, Buggisch P, Horban A, Lawitz E, Corbett C, Lenz O, Fevery B, Verbinnen T, Shukla U, Jessner W. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virol J 2018;15:26. [PMID: 29378602 DOI: 10.1186/s12985-018-0936-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
108 Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139-149. [PMID: 27910154 DOI: 10.1111/apt.13844] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
109 Cosar AM, Durand CM, Cameron AM, Gurakar A. Hepatitis C following liver transplantation: current approach and future research opportunities. Curr Opin Infect Dis 2016;29:346-52. [PMID: 27191202 DOI: 10.1097/QCO.0000000000000274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Kostadinova L, Shive CL, Zebrowski E, Fuller B, Rife K, Hirsch A, Compan A, Moreland A, Falck-Ytter Y, Popkin DL, Anthony DD. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathog Immun 2018;3:149-63. [PMID: 30370392 DOI: 10.20411/pai.v3i1.242] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
111 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
112 Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection? Lancet 2017;390:107-9. [PMID: 28699578 DOI: 10.1016/S0140-6736(17)31762-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
113 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
114 Younossi ZM. The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. Hepatology 2018;67:1160-2. [PMID: 29023922 DOI: 10.1002/hep.29580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
115 Parisi SG, Andreis S, Mengoli C, Menegotto N, Cavinato S, Scaggiante R, Andreoni M, Palù G, Basso M, Cattelan AM. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. Med Microbiol Immunol 2018;207:183-94. [PMID: 29523966 DOI: 10.1007/s00430-018-0538-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
116 Mazouz S, Boisvert M, Shoukry NH, Lamarre D. Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. CanLivJ 2018;1:78-105. [DOI: 10.3138/canlivj.1.2.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
117 Janjua NZ, Yu A, Kuo M, Alvarez M, Cook D, Wong J, Tyndall MW, Krajden M. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infect Dis. 2016;16:334. [PMID: 27436414 DOI: 10.1186/s12879-016-1683-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
118 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
119 Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. J Infect Dis 2016;214:1164-70. [PMID: 27485356 DOI: 10.1093/infdis/jiw332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
120 Salmon D, Mondelli MU, Maticic M, Arends JE; The ESCMID Study Group for Viral Hepatitis. The benefits of hepatitis C virus cure: Every rose has thorns. J Viral Hepat 2018;25:320-8. [DOI: 10.1111/jvh.12823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
121 Zaepfel M, Cristofaro L, Trawinski A, McCarthy K, Rightmier E, Khadem T. Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. Ann Pharmacother 2017;51:307-14. [PMID: 28228059 DOI: 10.1177/1060028016683495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
122 Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N, Keren-Naus A, Shemer-Avni Y, Mor O, Murad J, Novack V, Shlomai A. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Sci Rep 2020;10:17820. [PMID: 33082372 DOI: 10.1038/s41598-020-74568-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72 [PMID: 29147645 DOI: 10.5501/wjv.v6.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015;64:1824-33. [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 14.1] [Reference Citation Analysis]
125 Mohammed AQ, Auckle R, Li HL, Xu SL, Liu L, Zhao DD, Che WL. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. Am J Med Sci 2018;355:566-72. [PMID: 29891040 DOI: 10.1016/j.amjms.2018.02.001] [Reference Citation Analysis]
126 Ireland G, Simmons R, Hickman M, Harris R, Ramsay M, Sabin C, Mandal S. Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England. J Viral Hepat 2020;27:20-7. [PMID: 31505083 DOI: 10.1111/jvh.13203] [Reference Citation Analysis]
127 Smith SK, Rosenthal P. Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis. J Pediatr Gastroenterol Nutr 2016;63:516-7. [PMID: 27243422 DOI: 10.1097/MPG.0000000000001278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
128 Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wien Klin Wochenschr 2017;129:517-26. [PMID: 28130599 DOI: 10.1007/s00508-016-1162-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
129 Yun H, Zhao G, Sun X, Shi L. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open 2020;10:e035224. [PMID: 32819983 DOI: 10.1136/bmjopen-2019-035224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018;68:449-61. [PMID: 29476694 DOI: 10.1002/hep.29855] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 15.8] [Reference Citation Analysis]
131 Alswat K, Al-Sohaibani F, Khathlan A, Bashmail A, Alanazi M, Kurdi A, Almakadma AH, Al-Hamoudi W. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. Ann Saudi Med 2022;42:89-95. [PMID: 35380056 DOI: 10.5144/0256-4947.2022.89] [Reference Citation Analysis]
132 Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73:540-548. [PMID: 32243960 DOI: 10.1016/j.jhep.2020.03.031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
133 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
134 Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F;  ITA. LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update.Liver Int. 2021;41:585-597. [PMID: 33219585 DOI: 10.1111/liv.14735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
135 Gonzalez SA, Fierer DS, Talal AH. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat. 2017;16:S1-S23. [PMID: 28701904 DOI: 10.1097/adt.0000000000000104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
136 Sansom SE, Martin J, Adeyemi O, Burke K, Winston C, Markham S, Go B, Huhn G. Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infect Dis 2019;6:ofz099. [PMID: 30968054 DOI: 10.1093/ofid/ofz099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
137 Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect 2016;22:839-45. [PMID: 27677698 DOI: 10.1016/j.cmi.2016.09.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
138 Miri SM, Sharafi H, Salimi S, Bokharaei-salim F, Behnava B, Keshvari M, Karimi Elizee P, Keyvani H, Alavian SM. Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.46578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
139 Brown AN, Liu L, Rodriquez JL, Zhao L, Schuster L, Li E, Wang GP, Neely MN, Yamada W, Drusano GL. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Sci Rep 2017;7:14421. [PMID: 29089577 DOI: 10.1038/s41598-017-15007-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
140 Kiberd BA, Doucette K, Vinson AJ, Tennankore KK. Hepatitis C virus-infected kidney waitlist patients: Treat now or treat later? Am J Transplant 2018;18:2443-50. [PMID: 29687948 DOI: 10.1111/ajt.14891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
141 Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 2016;12:189-95. [PMID: 27596150 DOI: 10.1016/j.ebiom.2016.08.035] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
142 Sharafi H, Maleki S, Alavian SM. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Res 2019;259:54-61. [PMID: 30401643 DOI: 10.1016/j.virusres.2018.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
143 Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open 2019;3:210-6. [PMID: 31276038 DOI: 10.1002/jgh3.12139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
144 Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 2018;38 Suppl 1:139-145. [PMID: 29427487 DOI: 10.1111/liv.13659] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 20.3] [Reference Citation Analysis]
145 Dold L, Schwarze-Zander C, Boesecke C, Mohr R, Langhans B, Wasmuth JC, Strassburg CP, Rockstroh JK, Spengler U. Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA). Sci Rep 2019;9:12502. [PMID: 31467319 DOI: 10.1038/s41598-019-48756-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Vadaparampil ST, Fuzzell LN, Rathwell J, Reich RR, Shenkman E, Nelson DR, Kobetz E, Jones PD, Roetzheim R, Giuliano AR. HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017. Prev Med 2021;153:106222. [PMID: 32721414 DOI: 10.1016/j.ypmed.2020.106222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
148 Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116-25. [PMID: 31433302 DOI: 10.1016/j.jhep.2019.07.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
149 van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. Journal of Hepatology 2016;65:S95-S108. [DOI: 10.1016/j.jhep.2016.07.039] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 16.7] [Reference Citation Analysis]
150 Barré T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas Rojas T, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K, Chas J, Zaegel O, Chaix ML, Miailhes P, Serfaty L, Marcellin F, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology 2020;71:1182-97. [PMID: 31466125 DOI: 10.1002/hep.30914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7(1): 33-40 [PMID: 26855810 DOI: 10.4292/wjgpt.v7.i1.33] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
152 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
153 Rhodes T, Lancaster K. Evidence-making hepatitis C cure: Towards a science that knows more carefully. Int J Drug Policy 2019;72:40-6. [PMID: 31307851 DOI: 10.1016/j.drugpo.2019.06.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
154 Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-1464. [PMID: 30765123 DOI: 10.1016/s0140-6736(18)32111-1] [Cited by in Crossref: 207] [Cited by in F6Publishing: 77] [Article Influence: 69.0] [Reference Citation Analysis]
155 Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther 2019;17:311-25. [PMID: 30856022 DOI: 10.1080/14787210.2019.1588112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
156 Abdurakhmanov DT, Rozina TP, Nikulkina EN, Burnevich EZ, Tanashuk EL, Severov MV, Filatova AL, Milovanova SY, Karpov VV, Moiseev SV. [Antiviral therapy of chronic hepatitis C: 30 years success story]. Ter Arkh 2019;91:110-5. [PMID: 32598621 DOI: 10.26442/00403660.2019.11.000470] [Reference Citation Analysis]
157 Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8. [PMID: 27394647 DOI: 10.1016/S0140-6736(16)30579-7] [Cited by in Crossref: 725] [Cited by in F6Publishing: 377] [Article Influence: 120.8] [Reference Citation Analysis]
158 Bruno S, Boccaccio V, Russo ML, Maisonneuve P. Is the benefit of treating patients with cirrhosis proven? Liver Int. 2016;36 Suppl 1:21-27. [PMID: 26725893 DOI: 10.1111/liv.13013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
159 Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
160 Wu SH, Chu CJ, Lin CC, Su CW, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. J Chin Med Assoc 2019;82:186-90. [PMID: 30908411 DOI: 10.1097/JCMA.0000000000000069] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12216] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
162 Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2017;66:19-27. [PMID: 27545496 DOI: 10.1016/j.jhep.2016.08.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
163 Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. Transplantation. 2017;101:916-923. [PMID: 28060241 DOI: 10.1097/tp.0000000000001633] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.6] [Reference Citation Analysis]
164 McCombe G, Swan D, O'Connor E, Avramovic G, Vickerman P, Ward Z, Surey J, Macías J, Lambert JS, Cullen W. Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. JMIR Res Protoc 2018;7:e149. [PMID: 29866641 DOI: 10.2196/resprot.9043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
165 Wu S, Chu C, Su C, Lin C, Lee S, Wang Y, Lee F, Huang Y, Hou M. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association 2019;82:693-8. [DOI: 10.1097/jcma.0000000000000148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Salazar-Vizcaya L, Wandeler G, Fehr J, Braun D, Cavassini M, Stoeckle M, Bernasconi E, Hoffmann M, Rougemont M, Béguelin C, Rauch A; Swiss HIV Cohort Study . Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. Open Forum Infect Dis 2018;5:ofy154. [PMID: 30027103 DOI: 10.1093/ofid/ofy154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
167 Rhodes T, Lancaster K, Harris M, Treloar C. Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health 2018;29:260-73. [DOI: 10.1080/09581596.2018.1459475] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
168 Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Dig Liver Dis 2019;51:915-21. [PMID: 31031174 DOI: 10.1016/j.dld.2019.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
169 O'Neil CR, Buss E, Plitt S, Osman M, Coffin CS, Charlton CL, Shafran S. Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada. Can J Public Health 2019;110:714-21. [PMID: 31222618 DOI: 10.17269/s41997-019-00234-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Ireland G, Mandal S, Hickman M, Ramsay M, Harris R, Simmons R. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Euro Surveill 2019;24. [PMID: 31362807 DOI: 10.2807/1560-7917.ES.2019.24.30.1800695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
171 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
172 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
173 Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int. 2016;10:424-435. [PMID: 26758592 DOI: 10.1007/s12072-015-9691-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
174 Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell DL, Wilson JA. Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol Hepatol 2016;2016:5743521. [PMID: 27446849 DOI: 10.1155/2016/5743521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]